Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-019-00812-x
Abstract: At the request of French Regulatory Authorities, a new formulation of Levothyrox ® was licensed in France in 2017, with the objective of avoiding the stability deficiencies of an existing licensed formulation. Before launching the… read more here.
Keywords: bioequivalence; new formulation; formulation; levothyroxine ... See more keywords